ABSTRACT
Background The purpose of this study was to evaluate the necessity of COVID-19 vaccination in persons with prior COVID-19.
Methods Employees of Cleveland Clinic working in Ohio on Dec 16, 2020, the day COVID-19 vaccination was started, were included. Anyone who tested positive for COVID-19 at least once before the study start date was considered previously infected. One was considered vaccinated 14 days after receipt of the second dose of a COVID-19 mRNA vaccine. The cumulative incidence of COVID-19, symptomatic COVID-19, and hospitalizations for COVID-19, were examined over the next 10.5 months.
Results Among the 52238 employees, 4718 (9%) had prior COVID-19 at the start of the study, and 35113 (67%) had received at least two doses of the vaccine by the end of the study. Of the 4284 COVID-19 infections during the study, 3476 (81.1%) occurred in persons who were unvaccinated, and 4263 (99.5%) occurred among those without prior COVID-19. In Cox proportional hazards regression, both prior COVID-19 and vaccination were independently associated with significantly lower risk of COVID-19. Vaccination was associated with lower risk of COVID-19 among those without prior COVID-19 (HR 0.24, 95% CI 0.22–0.26) but not among those with prior COVID-19 (HR 0.86, 95% CI 0.33–2.29).
Conclusions Both previous infection and vaccination provide substantial protection against COVID-19. Vaccination reduces risk of COVID-19 among those without prior COVID-19 but not among those with prior COVID-19, at least not within one year following infection.
Summary Cumulative incidence of COVID-19 over 10.5 months, including the Delta phase, was examined among 52238 employees at Cleveland Clinic. Vaccination was associated with significantly lower risk of COVID-19 among those without prior COVID-19 but not among those with prior COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Cleveland Clinic Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.